A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

PHASE1RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

June 30, 2026

Conditions
Polycythemia Vera
Interventions
DRUG

9MW3011

Multiple dose

Trial Locations (6)

Unknown

RECRUITING

Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

RECRUITING

The Second Hospital of Tianjin Medical University, Tianjin

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY